1 Title

- 2 Effects of multiple-dose intranasal oxytocin treatment on social responsiveness in
- 3 children with autism: A randomized, placebo-controlled trial

4 Authors and affiliations

Daniels Nicky ^{a,c,*}, Moerkerke Matthijs ^{b,c,*}, Steyaert Jean ^c, Bamps Annelies ^c, Debbaut Edward
 ^{b,c}, Prinsen Jellina ^{a,c}, Tang Tiffany ^{b,c}, Van der Donck Stephanie ^{b,c}, Boets Bart ^{b,c,†}, Alaerts Kaat
 ^{a,c,†,*}

8 *Joined first-authorship, [†] senior authors

9 ^a KU Leuven, Department of Rehabilitation Sciences, Research Group for

- 10 Neurorehabilitation, Tervuursevest 101 box 1501, 3001 Leuven, Belgium.
- 11 ^b KU Leuven, Department of Neurosciences, Center for Developmental Psychiatry, O&N5b
- 12 Herestraat 49 box 7003, 3000 Leuven
- 13 ^cLeuven Autism Research consortium, KU Leuven, Leuven, Belgium
- 14
- 15 × Corresponding author.
- 16 Kaat Alaerts
- 17 KU Leuven, Department of Rehabilitation Sciences, Research Group for Neurorehabilitation,
- 18 Tervuursevest 101 box 1501, 3001 Leuven, Belgium.
- 19 E-mail: kaat.alaerts@kuleuven.be
- 20 Tel.: +32 16 37 64 46, Fax: +32 16 32 91 97

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 Abstract

22 In the past decade, intranasal administration of the neuropeptide oxytocin is increasingly 23 explored as a new treatment for reducing the core symptoms of autism spectrum disorder 24 (ASD). The efficacy of continual oxytocin treatment in school-aged children with ASD is, 25 however, not well established. Using a double-blind, randomized, placebo-controlled, parallel 26 design, the current trial explored the effects of four weeks of intranasal oxytocin treatment 27 (12 IU, twice daily) on social functioning in pre-pubertal school-aged children (aged 8-12 28 years, 61 boys, 16 girls). The double-blind phase was followed by a four-week single-blind 29 extension phase during which all participants received intranasal oxytocin. In the double-30 blind phase, no treatment-specific effects were identified in the primary outcome assessing 31 social functioning (parent-rated Social Responsiveness Scale), as well as on secondary 32 outcomes assessing repetitive behaviors, anxiety, and attachment. Exploratory moderator 33 analyses revealed that children who received the oxytocin treatment in combination with 34 concomitant psychosocial treatment displayed a greater benefit than those who received 35 psychosocial treatment or oxytocin alone. A modulating effect of parents' beliefs about allocated treatment was also identified, indicating that parents who believed their child 36 37 assigned to the active treatment reported greater benefit than those who believed their child 38 received placebo, particularly in the actual oxytocin group. Finally, participants who were 39 allocated to receive the placebo treatment during the double-blind phase of the trial and later 40 crossed-over to receive the active treatment during the single-blind extension phase, 41 displayed a significant within-group improvement in social responsiveness, over and above 42 the placebo-induced improvements noted in the first phase. While no overall treatment-43 specific improvements were identified, our results provide important indications that clinical 44 efficacy can be augmented when oxytocin administration is paired with targeted psychosocial 45 interventions that similarly stimulate socio-communicative behaviors. Future trials are urged 46 to further elucidate the potential of embedding oxytocin treatment within a socially stimulating 47 context.

48 Introduction

49 Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by 50 impairments in social communication and interaction, combined with restricted and repetitive 51 behaviors and interests (American Psychiatric Association, 2013). Thus far, the means of 52 treatment of ASD's core symptoms are primarily based on behavioral interventions (e.g., 53 stimulation of social communication, lessening the impairment due to restricted and repetitive 54 behaviors), since biomedical or pharmacological therapies targeting social impairment or 55 repetitive behaviors are largely unproven.

56 In the past decade, intranasal administration of the neuropeptide oxytocin (OT) has been 57 increasingly explored as a new treatment option for reducing ASD's social symptoms 58 (recently summarized in Huang et al., 2021). OT is an endogenous neuropeptide that is 59 mainly produced in paraventricular nuclei of the hypothalamus. In the brain, OT acts as an 60 important neuromodulator for a broad range of affiliative and prosocial behaviors, including 61 interpersonal bonding, social attunement and attachment (Bakermans-Kranenburg & van IJzendoorn, 2013; Bartz et al., 2011; Jurek & Neumann, 2018), presumably mediated 62 through its postulated top-down enhancing effect on 'social salience' and bottom-up effect on 63 64 regulating (social) stress and anxiety (Guastella & Hickie, 2016; Shamay-Tsoory & Abu-Akel, 65 2016).

Following a myriad of single-dose proof-of-principle studies (Alvares et al., 2017; Huang et 66 67 al., 2021), an initial multiple-dose pilot study assessed the safety and efficacy of six weeks of chronic intranasal OT treatment on core autism symptoms in 19 adults with ASD (10 68 receiving OT, 9 receiving placebo), and showed improved emotion recognition and quality of 69 70 life, and tentative improvements in repetitive behaviors after OT treatment (Anagnostou et 71 al., 2012). Later, Kosaka et al. (2016) showed significant improvements on the Clinical 72 Global Impression-Improvement scale after twelve weeks of OT treatment in adult men with 73 ASD, albeit only in the subgroup of participants receiving the high-dose treatment (32 IU/day; 74 n = 13), and not in the low-dose (16 IU; n = 15) or placebo groups (n = 16). In an exploratory 75 cross-over study by Watanabe et al. (2015), the effects of six weeks of daily intranasal OT administration on core autism characteristics were studied in 20 adult men with ASD, and 76 77 significant improvements in social reciprocity and social functioning (social-judgement task) 78 were identified. Yamasue et al. (2020) conducted a confirmatory trial with an identical 79 protocol as Watanabe et al. (2015) in 106 adult men with ASD (53 OT / 53 placebo). While 80 these authors identified significant improvements in terms of repetitive behaviors, the effects 81 on social reciprocity and social functioning could not be replicated. Bernaerts et al. (2020) 82 extended these observations in an exploratory sample of 40 young adult men with ASD (22

OT / 18 placebo), demonstrating long-term improvements in repetitive behaviors and feelings
of attachment after a four-week course which outlasted the period of administration till one
year post-treatment.

86 Given that ASD is an early-onset neurodevelopmental condition, it is important to extend 87 these insights to pediatric populations, allowing evaluations of OT treatment efficacy within 88 an early developmental window and whether it can be facilitatory for enriching social 89 behaviors and experiences from an early age onwards. To date, a handful of trials explored the effects of multiple-dose OT administration in children with ASD. Two initial trials reported 90 91 a consistent pattern of results, indicating improvements in the social domain (parent-reported 92 social responsiveness) after five weeks of intranasal OT treatment in 3-to-6-year-old children 93 (n = 31; cross-over; Yatawara et al., 2016) and after four weeks of treatment in 6-to-12-year-94 old children with ASD (14 OT / 18 placebo; Parker et al., 2017). No significant improvements 95 on core autism symptoms were demonstrated, however, after an eight-week OT treatment in adolescent boys with ASD (26 OT / 24 placebo; 12-18 years; Guastella et al., 2015) or in a 96 97 preliminary 12-week administration trial encompassing a broad age range of 5-to-17-year-old 98 children (8 OT / 10 placebo) with Phelan-McDermid syndrome (characterized by ASD 99 symptoms; Fastman et al., 2021). Also, in a recent confirmatory trial including 3-to-17-yearold children with ASD (139 OT / 138 placebo) and an age-adjusted dosing scheme ranging 100 101 from 8-80 IU, no improvements on outcomes of social functioning were evident after 24 102 weeks of OT treatment (Sikich et al., 2021).

Several factors have been put forward to understand these inconsistent results, ranging from heterogeneity in trial design (e.g., parallel versus cross-over design, adopted outcomes, dosing schema) to variation in participant characteristics. For instance, the well-powered confirmatory trial by Sikich et al. (2021) covered a broad age range (3-17 years), encompassing a critical period of pubertal development, which could have rendered heterogeneity due to differential physiologic effects of OT during different developmental stages (Geschwind, 2021).

110 Here, results are presented from a single-center, randomized, double-blind, placebo-111 controlled clinical trial (RCT with parallel design), testing efficacy on improvement in social 112 functioning and safety of multiple-dose OT treatment (four weeks of twice daily intranasal 113 administration of 12 IU) in a representative sample of 8-to-12-year-old children with ASD (40 114 OT / 40 placebo). Accordingly, this is the largest trial to date, examining OT treatment effects 115 in a relatively strict age range of pre-pubertal, school-aged children, aged 8 to 12 years, 116 thereby allowing to overcome some of the raised issues regarding sample heterogeneity. 117 Further, following prior observations of long-lasting retention effects of OT treatment in adults

with ASD (Bernaerts et al., 2020), the current trial also included a follow-up session four
weeks after cessation of the daily OT administrations, testing the possibility of crucial
retention effects in the current pediatric sample.

121 Methods

122 2.1. General study design

123 A single-center, two-arm, double-blind, randomized, placebo-controlled parallel study was 124 performed at the Leuven University Hospital (Leuven, Belgium) to assess effects of four 125 weeks of twice daily intranasal administration of OT on core autism characteristics, social 126 anxiety, and experience of attachment in school-aged children with ASD. The double-blind 127 phase (phase I) was followed by a four-week single-blind extension phase (phase II) during 128 which all participants received intranasal OT. In both phases, treatment effects were 129 assessed immediately after the four-week treatment (post) and at a follow-up session, four 130 weeks after cessation of the daily administrations (follow-up). See Figure 1, CONSORT Flow 131 diagram for number of participants randomized and analyzed.

Written informed consent from the parents and assent from the child were obtained prior to the study. Consent forms and study design were approved by the local Ethics Committee for Biomedical Research at the University of Leuven, KU Leuven (S61358) in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). The trial was registered at the European Clinical Trial Registry (Eudract 2018-000769-35) and the Belgian Federal Agency for Medicines and Health products.

138 2.2. Participants

139 Children with a formal diagnosis of ASD were recruited through the Autism Expertise Centre 140 at the Leuven University Hospital between July 2019 and January 2021. The diagnosis was 141 established by a multidisciplinary neuropediatric team based on the strict criteria of the DSM-142 5 (Diagnostic and Statistical Manual of Mental Disorders; American Psychiatric Association, 143 2013). Prior to randomization, the Autism Diagnostic Observation Schedule (ADOS-2; Lord 144 et al., 2012) and estimates of intelligence (four subtests of the Wechsler Intelligence Scale 145 for Children, Fifth Edition, Dutch version; Wechsler, 2018) were acquired (Table 1). Principal 146 inclusion criteria comprised a clinical diagnosis of ASD, age (8-12 years old), intelligence 147 quotient (IQ) above 70, native Dutch speaker, a stable background treatment for at least four 148 weeks prior to the screening and no anticipated changes during the trial. Only premenstrual 149 girls were included. Principal criteria for exclusion comprised any neurological (e.g., stroke, 150 epilepsy, concussion) or significant physical disorder (liver, renal, cardiac pathology) or prior

151 treatment with OT (Supplementary Table 1). The presence of comorbid psychiatric 152 disorders, current psychoactive medication use, and concomitant participation in 153 psychosocial therapies were screened for and logged (see Table 1 and Supplementary 154 Table 2).

A sample size of 40 participants in each treatment group was determined to be able to detect a medium effect size (d = 0.60) with $\alpha = 0.05$ and 80% power, corresponding to effect sizes previously reported in the four-week oxytocin trial with school-aged children by Parker et al., 2017.

159 2.3. Intervention

160 Study medication. Participants were randomized to receive OT (Syntocinon®, Sigma-tau) or placebo nasal sprays, administered in identical blinded amber 10 ml glass bottles with 161 162 metered pump. The placebo spray consisted of all the ingredients used in the active solution 163 except the OT compound. Nasal spray preparation, packaging, blinding and randomization 164 (permuted-block randomization, RITA software; Pahlke et al., 2004) was performed by the 165 pharmacy of Heidelberg University Hospital (Germany). Participants were randomly assigned 166 in a 1:1 ratio, with stratification according to gender. During the initial double-blind phase 167 (phase I), all research staff conducting the trial, participants and their parents were blinded to 168 treatment allocation. During the subsequent single-blind extension phase (phase II), 169 experimenters were aware that all participants received intranasal OT, but participants and 170 parents were still fully blinded regarding treatment allocation.

171 Dosing. Children (assisted by their parents) were asked to self-administer a daily dose of 2 x 172 12 IU nasal spray or placebo equivalent (3 puffs of 2 IU in each nostril), 12 IU in the morning 173 and 12 IU in the afternoon, during 28 consecutive days during the initial double-blind phase 174 (phase I), and for another 28 days during the single-blind extension phase (phase II). 175 Participants received clear instructions about use of the nasal sprays (based on Guastella et 176 al., 2013) through a demonstration together with the experimenter.

Compliance monitoring. Compliance was assured using a daily medication diary that recorded date and time of administration (phase I percentage compliance; OT: 96.75 ± 5.26%; placebo: 96.11 ± 5.29 %; t(74) = .52, p = .603; phase II percentage compliance; OTfirst: 94.55 ± 11.69%; placebo-first: 92.98 ± 13.92 %; t(74) = .53, p = .597). The total amount of administered fluid was also monitored (phase I: OT: 14.86 ± 2.37 ml; PL: 13.79 ± 2.35 ml; t(75) = 2.00, p = .050; phase II: OT-first: 13.72 ± 3.47 ml; placebo-first: 12.83 ± 3.52 ml; t(74)= 1.10, p = .275).

Side effects. During the course of the treatment, participants were screened for potential adverse events (weekly parent report) or changes in affect and arousal (daily diary by child and parent). Overall, reports of side effects were minimal and not treatment-specific (see Supplementary Tables 3 and 4).

188 Parent reported treatment beliefs. At the end of each trial phase (I and II), parents reported 189 beliefs about treatment allocation (see **Results** and **Figure 3**). In the double-blind phase 190 (phase I), the proportion of parents that believed their child had received the OT treatment 191 was similar in both treatment arms: 39.5% in the OT group, 35.9% in the placebo group (p =192 .75). In the OT group 18.4% of parents indicated to 'have no explicit belief' about treatment 193 allocation versus 10.3% in the placebo group. In the single blind phase (phase II), during which all participants received the actual OT treatment, 51.9% of the parents believed their 194 195 child received the OT treatment, 35.1% believed their child received the placebo treatment 196 and 13.0% indicated to 'have no explicit belief'.

197 2.4. Outcome Measures

198 The primary outcome measure was change from baseline in parent-rated social 199 responsiveness on the Social Responsiveness Scale-Children, second edition (SRS-2; Constantino & Gruber, 2012; Roeyers et al., 2015). which comprises four subscales 200 201 social communication, examining social awareness, social motivation, and 202 rigidity/repetitiveness, using a four-point Likert-scale (65 items). Higher scores indicate 203 greater deficit.

Secondary outcome measures included changes from baseline in parent-rated repetitive behaviors (Repetitive Behavior Scale-Revised (RBS-R; Bodfish et al., 2000), self and parentrated presence of anxiety symptoms (Screen for Child Anxiety Related Emotional Disorders (SCARED-NL: Muris et al., 2007), and changes from baseline in constructs of self-rated attachment towards their mother (Attachment Questionnaire child-report; Bosmans et al., 2014) and peers (Attachment Style Classification Questionnaire child-report; Finzi et al., 2000) (see also **Supplementary Table 5**).

All outcomes were assessed five times: (i) at baseline, (ii) immediately after the four-week double-blind treatment (phase I - post); (iii) at a follow-up session, four weeks after cessation of the double-blind treatment (phase I - follow-up); (iv) immediately after the four-week single-blind treatment (phase II - post); and (v) at a follow-up session four weeks after cessation of the single-blind treatment (phase II - follow-up). Post sessions were scheduled approximately 24h after the last administration, follow-up sessions within 28 ± 7 days.

217 2.5. Data Analysis

Analyses were performed using a modified intention-to-treat approach that included all randomized participants who completed the baseline session and at least one post or followup session (see **Figure 1**, **CONSORT flow-chart**). All statistics were executed with Statistica 14 (Tibco Software Inc.).

222 First, as outlined in **Table 1**, possible baseline differences between treatment groups on the 223 primary or secondary outcomes were assessed using independent sample t-tests, but no 224 statistically significant differences were identified. Next, between-group differences in 225 treatment responses of phase I (double-blind) on the primary and secondary outcome 226 measures were assessed, by subjecting change from baseline scores of the post and follow-227 up session to independent sample t-tests. Additionally, single-sample t-tests were adopted to 228 assess within-group changes (compared to baseline) in the OT and placebo group 229 separately.

230 Subsequent exploratory analyses of the primary outcome were performed to investigate the 231 potential influence of possible moderator variables on phase I treatment outcome. To do so, change from baseline scores of the primary outcome (SRS-2) were subjected to general 232 linear models with the within-subject factor 'assessment session' (post, follow-up) and the 233 234 between-subject factors 'treatment' (OT, placebo) and specific moderator variables. Separate 235 models were constructed to assess the modulating effect of concomitant psychosocial 236 treatments (present, not present); medication use (present, not present; as listed in Table 1); 237 and parent reported beliefs (OT, placebo).

To evaluate the effect of phase, within-subject changes from *phase I (double-blind) to phase II (single-blind extension)* were assessed, across groups and separately within the OT-first and placebo-first groups. To do so, change from baseline scores of the primary outcome (SRS-2) were subjected to general linear models with the within-subject factors 'assessment session' (post, follow-up) and 'phase' (phase I, phase II).

Finally, to assess whether the magnitude of the observed change from baseline scores at the last session of the trial were reliable for individual participants (more than can be expected by measurement error), the Reliable Change Index (RCI) as proposed by Jacobson et al. (1999) was calculated, based on the test-retest reliability of the adopted Dutch parent-reported SRS scale (Cronbach's alpha = .94; Roeyers et al., 2015). Change scores higher than the RCIvalue (14.8) were considered reliable.

249 **Results**

250 Double-blind phase (phase I)

251 Between-group analyses revealed no significant effect of treatment on the primary outcome parent-reported social responsiveness (SRS-2), either immediately post-treatment (p = .839), 252 253 or at the follow-up session, four weeks after cessation of the daily nasal spray 254 administrations (p = .626) (see **Table 2** and **Supplementary Table 6** for the raw scores). 255 Both groups displayed similar significant pre-to-post-treatment improvements in social 256 responsiveness (reduced SRS-2 scores) immediately after treatment (OT: p = .017; placebo: 257 p = .009) and at the follow-up session (OT: p = .001; placebo: p = .017). A similar pattern of 258 non-treatment-specific improvements was evident for the secondary outcomes (Table 2).

Interestingly, exploratory moderator analyses showed a significant interaction between 259 260 treatment and the presence of **concomitant psychosocial treatment** (F(1,72) = 6.87; p =261 .011; Figure 2), indicating that, across assessment sessions (post, follow-up), participants 262 who received the OT treatment combined with psychosocial treatment displayed greater 263 benefits compared to children receiving only psychosocial treatment (combined with placebo) 264 (t(26) = 2.40; p = .012, one-tailed) or only the OT treatment (t(36) = 1.90; p = .033, one-tailed)265 tailed). In children without psychosocial treatment, OT treatment responses were not 266 significantly different from those in the placebo group (t(46) = 1.40; p = .084, one-tailed). 267 None of the other main or interaction effects (e.g., with assessment session) were significant 268 (all, p > .05).

269 In terms of modulating effects of parent reported beliefs, a trend-level interaction with 270 'assessment session' was evident (F(1,61) = 3.22; p = .077), indicating that the parents' own 271 belief about allocated treatment differentially modulated treatment responses at the post and follow-up assessment session (Figure 3). Direct exploration of this effect, separately for each 272 273 treatment group, showed that for participants receiving the actual OT treatment, parents' own 274 belief moderated treatment immediately post-treatment (t(29) = -3.18; p = .001, one-tailed), 275 but no longer at the follow-up session (t(29) = -1.02; p = .158, one-tailed). Specifically, 276 parents who believed their child had received OT, reported significantly greater 277 improvements in social responsiveness immediately post-treatment, compared to those who 278 believed their child had received placebo. In the placebo group, no significant modulations of 279 treatment responses were evident either immediately post-treatment (t(32) = -.32; p = .374. 280 one-tailed) or at the follow-up session (t(32) = .37; p = .358, one-tailed). None of the other 281 main or interaction effects were significant (all, p > .05). Further, for concomitant 282 **medication use**, no significant modulating effects were evident (all, p > .148).

283 Single-blind extension phase (phase II)

Examination of within-subject changes from phase I to phase II yielded a significant effect of 'phase' (F(1,70) = 12.94; p < .001), but no 'phase x treatment interaction' (F(1,70) = 2.24; p =.14), indicating a further improvement in social responsiveness across treatment groups from phase I to phase II, (**Figure 4** and **Supplementary Table 6** for the raw scores). The main effects of treatment and assessment session were not significant (p > .05).

289 When examined separately for each treatment group, the effect of phase was particularly 290 strong in the placebo-first group (F(1,35) = 14.54; p < .001), indicating that for children who 291 crossed over from placebo (in phase I) to OT treatment (in phase II), improvements in social 292 responsiveness were significantly more pronounced in phase II, during which the child 293 received the actual OT treatment (**Figure 4**, **right panel**).

294 Within the OT-first group, only non-significant within-subject changes from phase I to phase II 295 were noted (F(1,35) = 1.99; p = .17), indicating that OT treatment effects of phase I were not 296 significantly augmented by receiving the additional four-week OT treatment of phase II. 297 Analysis of the OT-first group did reveal a significant effect of 'session', indicating that 298 irrespective of phase, treatment-related improvements were more pronounced at the follow-299 up session, compared to the post session (F(1,35) = 6.11; p = .018), with maximal treatment 300 responses at the last assessment session of the trial (four-week follow-up of phase II: Figure 301 4, left panel).

302 Accordingly, at the last session of the trial, both the OT-first (receiving a total of eight weeks 303 of OT treatment) and the placebo-first group (receiving a total of four weeks of OT treatment) 304 displayed significant pre-to-post improvements in social responsiveness (OT-first; pre-post 305 change: -9.61 ± 12.18 ; t(35) = -4.74; p < .001; (placebo-first; pre-post change: -9.81 ± 14.83 ; 306 t(35) = -3.97; p < .001). In the OT-first group, 27 (out of 36: 75%) participants displayed a pre-307 to-post improvement, and this change was identified to be reliable for 12 participants (higher 308 than the Reliable Change Index: >14.8). Similarly, also in the PL-first group, 27 (out of 36: 309 75%) participants displayed a pre-to-post improvement at the last session of the trial, which was reliable for 11 participants. 310

311 **Discussion**

312 The current pediatric trial with pre-pubertal school-aged children with ASD demonstrated no 313 significant treatment-specific effects of four weeks of intranasal OT administration on the 314 primary outcome, assessing parent-rated social responsiveness (SRS-2), nor on the 315 secondary outcomes assessing parent and child self-reports of repetitive behaviors, anxiety, 316 and attachment. Both the OT and the placebo group displayed similar improvements, both 317 immediately after the multiple-dose treatment and at the four-week follow-up session. 318 Notably, exploratory analyses showed that children who received the OT treatment in 319 combination with concomitant psychosocial treatment displayed a greater improvement in 320 social responsiveness than those who received psychosocial treatment or OT alone. A 321 modulating effect of parents' belief about allocated treatment was also identified, indicating 322 that parents who believed their child had been assigned the active treatment reported greater 323 benefit than those who believed their child received placebo, particularly in the experimental 324 group receiving actual OT. Finally, participants who were allocated to receive the placebo 325 treatment during the first double-blind phase of the trial and later crossed-over to receive the 326 active treatment during the second (single-blind) phase, displayed a significant improvement 327 in social responsiveness, over and above the 'placebo-induced' improvement noted in the 328 first phase. The next sections will address these observations in more detail.

329 The results of earlier continual OT trials in children with ASD have been equivocal: some with 330 beneficial outcomes (Parker et al., 2017; Yatawara et al., 2016), while others without 331 significant effect (Fastman et al., 2021; Guastella et al., 2015; Sikich et al., 2021). While it is 332 difficult to pinpoint the different factors contributing to variability in study results, several key 333 differences in adopted dosing schema, trial design, and participant demographics have been 334 put forward as important moderators. Furthermore, the particular context in which the OT 335 treatment is administered is also increasingly put forward as a vital factor for understanding 336 variability in treatment responses within and across studies. Initial single-dose administration 337 studies already noted that acute effects of OT can be modulated by contextual factors, 338 indicating for instance that OT-induced facilitation of cooperation and trust is most 339 pronounced towards in-group members, but is diminished, absent or even reversed towards 340 out-group members, particularly within threat-emanating contexts (de Dreu et al., 2010; 341 Mikolajczak et al., 2010). Also, in an early study by Heinrichs et al (2003), stress-reducing 342 effects of OT were significantly augmented when accompanied by a supportive context (i.e., 343 social support from a friend).

Against this background, it has been theorized that OT may indeed open a 'window of opportunity' to enhance prosocial behavior, but its potential can only be fully realized when

346 OT treatment is paired with a supportive context, such as effective concomitant behavioral 347 interventions that can support social skill development and improve prosocial behavior (Ford 348 & Young, 2021; Geschwind, 2021). In line with this notion, exploratory assessments within 349 our current trial revealed a significant synergetic modulation of treatment response related to 350 the presence of concomitant psychosocial treatment during the course of the OT trial 351 (screened through parent report, see Table 1), indicating maximal treatment effects in 352 children receiving the OT treatment in combination with ongoing psychosocial treatment. 353 Administration of OT as an adjunct to other therapeutic approaches has been explored 354 before. For example, in a study with schizophrenic patients, a six-week (12 session) social 355 cognition training was combined with OT administration (shortly before the start of each 356 session), and a significant improvement in empathic accuracy was observed (Davis et al., 357 2014). Also, in patients with social anxiety disorders, OT treatment administered as an 358 adjunct to 4 sessions of public speaking-exposure therapy induced significant improvements in mental representations of the self (Guastella et al., 2009). While preliminary, a pilot 6-week 359 360 OT administration study in which parents were stimulated to systematically engage with their 361 child in a positive social interaction or play session in the first hour after spray administration, 362 vielded unanimously positive treatment outcomes in 3-to-8-year-old children with ASD (n = 363 46), both in terms of social improvements and repetitive behaviors (Le et al., 2022). 364 Together, these and our study highlight the relevance of context and urge future clinical trials 365 to further elucidate whether clinical efficacy can be augmented when OT administration is 366 paired with targeted behavioral interventions that support similar states and (social) 367 behaviors.

368 Another notable observation was the identification that the parent's belief about allocated 369 treatment constituted a potentially important moderator of treatment response, indicating 370 that - within the OT group - parents who believed their child had been assigned the active 371 treatment reported greater benefit than those who believed their child received placebo. 372 Notably, the modulation was only significant in the group receiving the actual OT treatment, 373 not in the placebo group, and only for the immediate post-treatment outcome assessment, 374 not for the four-week follow-up assessment. These results therefore only partly concur with a 375 prior negative OT trial in which moderator effects by parent belief were evident, both in the 376 actual OT group, as well as in the placebo group (Guastella et al., 2015). One the one hand, 377 the modulation by parents' belief may reflect an expectancy bias, as noted in many prior 378 studies, especially in pediatric trials (King et al., 2009). Particularly in relation to OT 379 intervention research, increased biases can be expected, considering the large media coverage and hype about purported prosocial benefits of the OT "love hormone" that may 380 381 eventually impact parents' expectancies (Guastella et al., 2015). However, a sole effect of 382 expectancy bias may be unlikely, since in that case, one would expect response modulations 383 to be present both in the OT and placebo groups. Since the modulating effect was specific to 384 the OT group, the possibility cannot be ruled out that parents may have actually correctly identified real treatment responders, yielding maximal treatment responses in a particular 385 386 subgroup of children that displayed actual beneficial effects. Further, in line with the notion 387 that context may constitute an important moderator of treatment, one could also envisage 388 that parents who believed their child to receive the active treatment, may have provided their 389 children with more active socio-interactive family contexts during the four-week treatment 390 period, i.e., prompting them to increasingly engage in social experiences and learning, 391 thereby effectively boosting treatment responses.

392 Another important result relates to the observation that children who crossed over from 393 placebo (in phase I) to the actual OT treatment (in phase II), showed a significant further 394 improvement in social responsiveness over and above the substantial placebo-induced 395 improvement noted in phase I. Trial designs in which a phase of blinded placebo intervention 396 is administered before actual treatment allocation have been put forward before as an 397 efficient method to control for placebo effects and to improve detection of 'real' therapeutic 398 responses (Yatawara et al., 2016). The current observation of a significant further 399 improvement from a blinded placebo phase (double-blinded) to the active treatment (single-400 blinded) provides support to this notion. While not explicitly addressed in the current study, it 401 is also noteworthy to stipulate that the oxytocinergic system itself has been suggested to 402 form a key mediator for facilitating placebo-induced improvements. Indeed, as postulated in 403 the recent oxytocin-placebo account of Itskovich et al. (2022); OT is suggested to mediate 404 social facilitation of placebo effects, an effect that is thought to be facilitated by increased 405 social connectedness between patient and clinician during trial participation. In line with this 406 notion, a prior OT administration trial showed that placebo-induced improvements in social 407 functioning coincided with endogenous increases in oxytocin secretion (Parker et al., 2017)

408 Further, in our trial, children who received the actual OT treatment in the first phase and 409 crossed over to a second phase of active treatment, showed only non-significant within-410 subject improvements from phase I to phase II, particularly at the four-week follow-up 411 session of phase II - supporting prior observations of a retention of OT's beneficial effects, 412 also after cessation of the daily nasal spray administrations (Alaerts et al., 2020; Bernaerts et 413 al., 2020). It is noted indeed, that at the last follow-up session of the trial, the majority of 414 children of both the OT-first group and the placebo-first group displayed (reliable) beneficial 415 effects in social responsiveness, indicating that both an eight-week (with a four-week break 416 in the middle) or a continual four-week OT treatment were similarly able to induce a 417 significant beneficial outcome on a core ASD symptom domain. This observation adds to the

418 field's uncertainty regarding to-be-administered dosing schemas and durations. In multiple-419 dose OT trials with individuals with ASD, daily dosing ranged from 8-80 IU and durations 420 from 4 continual days to 24 weeks, but strong empirical support for favoring one dosing 421 scheme over another is currently lacking. Some earlier single-dose trials suggested dose-422 response curves to exhibit U-shaped forms (Lieberz et al., 2020; Spengler et al., 2017), a 423 notion that is supported by a recent chronic four-week OT administration trial in ASD, 424 identifying a daily total dose of 6 IU of TTA-121 (a new formulation of intranasal OT spray 425 with an enhanced bioavailability) to be the most efficacious one, compared to a lower (3 IU) 426 or higher (10 IU) daily dose (Yamasue et al., 2022). Furthermore, in terms of dosing scheme, 427 recent work showed that intermittent (every other day) administration may be therapeutically 428 more efficient than continual administration to obtain anxiolytic effects and reduce amygdala 429 reactivity (Kou et al., 2020). These observations were attributed to reflect a desensitization of 430 the endogenous oxytocinergic system upon too high concentrations and/or too high 431 frequencies of exogenous OT administration. The current observation that a single four-week 432 course can yield the same beneficial effects as a twice four-week course therefore reinforces 433 the notion that longer treatment durations do not necessarily facilitate higher treatment 434 responses. Similarly, in a recent large-scale trial administering OT over a 24-week period, it 435 was noted that the long duration might have attenuated initial early responses to OT (Sikich et al., 2021). In light of these observations, future trials should be directed at identifying the 436 437 optimal dosing, administration length, and intervals of intranasal OT administration.

438 To conclude, while the current study showed no overall treatment-specific improvements, 439 important moderator effects were identified, providing initial indications that clinical efficacy 440 can be augmented when OT administration is paired with targeted behavioral interventions 441 that support similar states and (social) behaviors. Future trials are urged to further elucidate 442 the potential of embedding OT treatment within a (socially) stimulating context. Also, the role 443 of parental belief in modulating OT treatment responses needs further attention in 444 subsequent clinical trials. Finally, the observation that (reliable) improvements were 445 established in a large subset of children at the last session of the trial, either after a single 446 four-week course or after two four-week courses, should stimulate future trials to further 447 identify optimal dosing schemas, not only in terms of (daily) concentration, but also in terms 448 of administration length and the possibility of intermittent dosing.

449 Funding and Disclosure

This research was supported by an internal C1 fund of the KU Leuven [ELG-D2857-C14/17/102], a Doctor Gustave Delport fund of the King Baudouin Foundation and the Branco Weiss fellowship of the Society in Science - ETH Zurich granted to KA. JP is supported by the Marguerite-Marie Delacroix foundation and a postdoctoral fellowship of the Flanders Fund for Scientific Research (FWO; 1257621N).

The funding sources had no further role in study design, data collection, analysis and interpretation of data, writing of the report or in the decision to submit the paper for publication.

458 **Conflict of Interest**

459 All authors declare that they have no conflicts of interest.

460 Acknowledgements

We would like to thank all the participants of the study and our colleagues of the LeuvenAutism Research Consortium (LAuRes).

463 **References**

- Alaerts, K., Bernaerts, S., Prinsen, J., Dillen, C., Steyaert, J., & Wenderoth, N. (2020).
 Oxytocin induces long-lasting adaptations within amygdala circuitry in autism: a
- 466 treatment-mechanism study with randomized placebo-controlled design.
- 467 *Neuropsychopharmacology*, *45*(7), 1141–1149. https://doi.org/10.1038/s41386-020-
- 468 0653-8
- Alvares, G. A., Quintana, D. S., & Whitehouse, A. J. O. (2017). Beyond the hype and hope:
 Critical considerations for intranasal oxytocin research in autism spectrum disorder. *Autism Research*, *10*(1), 25–41. https://doi.org/10.1002/aur.1692
- 472 American Psychiatric Association. (2013). *Diagnostic and Statistical Manual of Mental*473 *Disorders (DSM-5®)* (5th ed.). American Psychiatric Association.
 474 https://doi.org/10.1176/appi.books.9780890425596
- Anagnostou, E., Soorya, L., Chaplin, W., Bartz, J., Halpern, D., Wasserman, S., Wang, A. T.,
 Pepa, L., Tanel, N., Kushki, A., & Hollander, E. (2012). Intranasal oxytocin versus
 placebo in the treatment of adults with autism spectrum disorders: a randomized
 controlled trial. *Molecular Autism*, *3*(1). https://doi.org/10.1186/2040-2392-3-16
- Bakermans-Kranenburg, M. J., & van IJzendoorn, M. H. (2013). Sniffing around oxytocin:
 review and meta-analyses of trials in healthy and clinical groups with implications for
 pharmacotherapy. *Translational Psychiatry*, *3*(5), 1–14.
 https://doi.org/10.1038/TP.2013.34
- Bartz, J. A., Zaki, J., Bolger, N., & Ochsner, K. N. (2011). Social effects of oxytocin in
 humans: context and person matter. *Trends in Cognitive Sciences*, *15*(7), 301–309.
 https://doi.org/10.1016/J.TICS.2011.05.002

Bernaerts, S., Boets, B., Bosmans, G., Steyaert, J., & Alaerts, K. (2020). Behavioral effects
of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial
with long-term follow-up. *Molecular Autism*, *11*(1). https://doi.org/10.1186/S13229-0200313-1

- Bodfish, J. W., Symons, F. J., Parker, D. E., & Lewis, M. H. (2000). Varieties of repetitive
 behavior in autism: comparisons to mental retardation. *Journal of Autism and Developmental Disorders*, *30*(3), 237–243. https://doi.org/10.1023/A:1005596502855
- Bosmans, G., van de Walle, M., Goossens, L., & Ceulemans, E. (2014). (In)variability of
 attachment in middle childhood: Secure base script evidence in diary data. *Behaviour Change*, *31*(4), 225–242. https://doi.org/10.1017/BEC.2014.18
- 496 Constantino, J. N., & Gruber, C. P. (2012). Social responsiveness scale (2nd. ed.). Manual.
 497 Western Psychological Services.
- 498 Davis, M. C., Green, M. F., Lee, J., Horan, W. P., Senturk, D., Clarke, A. D., & Marder, S. R.
 499 (2014). Oxytocin-Augmented Social Cognitive Skills Training in Schizophrenia.
 500 *Neuropsychopharmacology*, *39*(9), 2070. https://doi.org/10.1038/NPP.2014.68
- de Dreu, C. K. W., Greer, L. L., Handgraaf, M. J. J., Shalvi, S., van Kleef, G. A., Baas, M.,
 ten Velden, F. S., van Dijk, E., & Feith, S. W. W. (2010). The neuropeptide oxytocin
 regulates parochial altruism in intergroup conflict among humans. *Science (New York, N.Y.)*, *328*(5984), 1408–1411. https://doi.org/10.1126/SCIENCE.1189047

- Fastman, J., Foss-Feig, J., Frank, Y., Halpern, D., Harony-Nicolas, H., Layton, C., Sandin,
 S., Siper, P., Tang, L., Trelles, P., Zweifach, J., Buxbaum, J. D., & Kolevzon, A. (2021).
 A randomized controlled trial of intranasal oxytocin in Phelan-McDermid syndrome. *Molecular Autism*, *12*(1). https://doi.org/10.1186/s13229-021-00459-1
- Finzi, R., Cohen, O., Sapir, Y., & Weizman, A. (2000). Attachment styles in maltreated
 children: a comparative study. *Child Psychiatry and Human Development*, *31*(2), 113–
- 511 128. https://doi.org/10.1023/A:1001944509409
- Ford, C. L., & Young, L. J. (2021). Refining oxytocin therapy for autism: context is key. *Nature Reviews Neurology 2021 18:2*, *18*(2), 67–68. https://doi.org/10.1038/S41582021-00602-9
- 515 Geschwind, D. H. (2021). Oxytocin for Autism Spectrum Disorder Down, but Not Out. New
 516 England Journal of Medicine, 385(16), 1524–1525.
 517 https://doi.org/10.1056/NEJME2110158/SUPPL_FILE/NEJME2110158_DISCLOSURES
 518 .PDF
- Guastella, A. J., Gray, K. M., Rinehart, N. J., Alvares, G. A., Tonge, B. J., Hickie, I. B.,
 Keating, C. M., Cacciotti-Saija, C., & Einfeld, S. L. (2015). The effects of a course of
 intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum
 disorders: a randomized controlled trial. *Journal of Child Psychology and Psychiatry,*and Allied Disciplines, 56(4), 444–452. https://doi.org/10.1111/JCPP.12305
- Guastella, A. J., & Hickie, I. B. (2016). Oxytocin treatment, circuitry, and autism: A critical
 review of the literature placing oxytocin into the autism context. *Biological Psychiatry*,
 79(3), 234–242. https://doi.org/10.1016/j.biopsych.2015.06.028
- Guastella, A. J., Hickie, I. B., McGuinness, M. M., Otis, M., Woods, E. A., Disinger, H. M.,
 Chan, H. K., Chen, T. F., & Banati, R. B. (2013). Recommendations for the
 standardisation of oxytocin nasal administration and guidelines for its reporting in
 human research. *Psychoneuroendocrinology*, *38*(5), 612–625.
- 531 https://doi.org/10.1016/J.PSYNEUEN.2012.11.019
- Guastella, A. J., Howard, A. L., Dadds, M. R., Mitchell, P., & Carson, D. S. (2009). A
 randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for
 social anxiety disorder. *Psychoneuroendocrinology*, *34*(6), 917–923.
 https://doi.org/10.1016/J.PSYNEUEN.2009.01.005
- Heinrichs, M., Baumgartner, T., Kirschbaum, C., & Ehlert, U. (2003). Social support and
 oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. *Biological Psychiatry*, *54*(12), 1389–1398. https://doi.org/10.1016/S00063223(03)00465-7
- Huang, Y., Huang, X., Ebstein, R. P., & Yu, R. (2021). Intranasal oxytocin in the treatment of
 autism spectrum disorders: A multilevel meta-analysis. *Neuroscience and Biobehavioral Reviews*, *122*, 18–27. https://doi.org/10.1016/j.neubiorev.2020.12.028
- Itskovich, E., Bowling, D. L., Garner, J. P., & Parker, K. J. (2022). Oxytocin and the social
 facilitation of placebo effects. *Molecular Psychiatry 2022*, 1–10.
 https://doi.org/10.1038/S41380-022-01515-9
- Jacobson, N. S., Roberts, L. J., Berns, S. B., & McGlinchey, J. B. (1999). Methods for
 defining and determining the clinical significance of treatment effects: Description,

application, and alternatives. *Journal of Consulting and Clinical Psychology*, 67(3), 300–
307. https://doi.org/10.1037/0022-006X.67.3.300

- Jurek, B., & Neumann, I. D. (2018). The Oxytocin Receptor: From Intracellular Signaling to
 Behavior. *Physiological Reviews*, *98*(3), 1805–1908.
 https://doi.org/10.1152/PHYSREV.00031.2017
- King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., Donnelly,
 C. L., Anagnostou, E., Dukes, K., Sullivan, L., Hirtz, D., Wagner, A., & Ritz, L. (2009).
 Lack of efficacy of citalopram in children with autism spectrum disorders and high levels
 of repetitive behavior: citalopram ineffective in children with autism. *Archives of General Psychiatry*, *66*(6), 583–590. https://doi.org/10.1001/ARCHGENPSYCHIATRY.2009.30
- Kosaka, H., Okamoto, Y., Munesue, T., Yamasue, H., Inohara, K., Fujioka, T., Anme, T.,
 Orisaka, M., Ishitobi, M., Jung, M., Fujisawa, T. X., Tanaka, S., Arai, S., Asano, M.,
 Saito, D. N., Sadato, N., Tomoda, A., Omori, M., Sato, M., ... Wada, Y. (2016). Oxytocin
 efficacy is modulated by dosage and oxytocin receptor genotype in young adults with
 high-functioning autism: a 24-week randomized clinical trial. *Translational Psychiatry*,
 6(8), e872. https://doi.org/10.1038/TP.2016.152
- Kou, J., Zhang, Y., Zhou, F., Sindermann, C., Montag, C., Becker, B., & Kendrick, K. M.
 (2020). A randomized trial shows dose-frequency and genotype may determine the
 therapeutic efficacy of intranasal oxytocin. *Psychological Medicine*, 1–10.
 https://doi.org/10.1017/S0033291720003803
- Le, J., Zhang, L., Zhao, W., Zhu, S., Lan, C., Kou, J., Zhang, Q., Zhang, Y., Li, Q., Chen, Z.,
 Fu, M., Montag, C., Zhang, R., Yang, W., Becker, B., & Kendrick, K. M. (2022).
 Infrequent intranasal oxytocin followed by positive social interaction improves symptoms
 in autistic children: a randomized clinical trial. *MedRxiv*, 2022.01.03.22268708.
 https://doi.org/10.1101/2022.01.03.22268708
- Lieberz, J., Scheele, D., Spengler, F. B., Matheisen, T., Schneider, L., Stoffel-Wagner, B.,
 Kinfe, T. M., & Hurlemann, R. (2020). Kinetics of oxytocin effects on amygdala and
 striatal reactivity vary between women and men. *Neuropsychopharmacology*, *45*(7),
 1134. https://doi.org/10.1038/S41386-019-0582-6
- Lord, C., Rutter, M., DiLavore, P. C., Risi, S., Gotham, K., & Bishop, S. L. (2012). Autism
 Diagnostic Observation Schedule: ADOS-2. Western Psychological Services.
- 579 Mikolajczak, M., Gross, J. J., Lane, A., Corneille, O., de Timary, P., & Luminet, O. (2010).
 580 Oxytocin Makes People Trusting, Not Gullible. *Psychological Science*, *21*(8), 1072–
 581 1074. https://doi.org/10.1177/0956797610377343
- Muris P., Bodden D., Hale W, Birmaher B, & Mayer B. (2007). SCARED-NL. Vragenlijst over
 angst en bang-zijn bij kinderen en adolescenten. Handleiding bij de gereviseerde
 Nederlandse versie van de Screen for Child Anxiety Related Emotional Disorders.
 Boom test uitgevers.
- Pahlke, F., König, I., & Ziegler, A. (2004). Randomization In Treatment Arms (RITA): Ein
 Randomisierungs-Programm für klinische Studien. *Inform Biom Epidemiol Med Biol*, 35,
 1–22.
- Parker, K. J., Oztan, O., Libove, R. A., Sumiyoshi, R. D., Jackson, L. P., Karhson, D. S.,
 Summers, J. E., Hinman, K. E., Motonaga, K. S., Phillips, J. M., Carson, D. S., Garner,
 J. P., & Hardan, A. Y. (2017). Intranasal oxytocin treatment for social deficits and

- 592 biomarkers of response in children with autism. *Proceedings of the National Academy of* 593 *Sciences of the United States of America*, *114*(30), 8119–8124.
- 594 https://doi.org/10.1073/PNAS.1705521114
- Roeyers, H., Thys, M., Druart, C., de Schryver, M., & Schittekatte, M. (2015). SRS-2:
 Screeningslijst voor autismespectrumstoornissen. Hogrefe Uitgevers.
- Shamay-Tsoory, S. G., & Abu-Akel, A. (2016). The Social Salience Hypothesis of Oxytocin.
 Biological Psychiatry, *79*(3), 194–202.
- 599 https://doi.org/10.1016/J.BIOPSYCH.2015.07.020
- Sikich, L., Kolevzon, A., King, B. H., McDougle, C. J., Sanders, K. B., Kim, S.-J., Spanos, M.,
 Chandrasekhar, T., Trelles, M. D. P., Rockhill, C. M., Palumbo, M. L., Witters Cundiff,
 A., Montgomery, A., Siper, P., Minjarez, M., Nowinski, L. A., Marler, S., Shuffrey, L. C.,
 Alderman, C., ... Veenstra-VanderWeele, J. (2021). Intranasal Oxytocin in Children and
 Adolescents with Autism Spectrum Disorder. *New England Journal of Medicine*,
 385(16), 1462–1473.
- 606 https://doi.org/10.1056/NEJMOA2103583/SUPPL_FILE/NEJMOA2103583_DATA-607 SHARING.PDF
- Spengler, F. B., Schultz, J., Scheele, D., Essel, M., Maier, W., Heinrichs, M., & Hurlemann,
 R. (2017). Kinetics and Dose Dependency of Intranasal Oxytocin Effects on Amygdala
 Reactivity. *Biological Psychiatry*, *82*(12), 885–894.
 https://doi.org/10.1016/J.BIORSXCH.2017.04.015
- 611 https://doi.org/10.1016/J.BIOPSYCH.2017.04.015
- Watanabe, T., Kuroda, M., Kuwabara, H., Aoki, Y., Iwashiro, N., Tatsunobu, N., Takao, H.,
 Nippashi, Y., Kawakubo, Y., Kunimatsu, A., Kasai, K., & Yamasue, H. (2015). Clinical
 and neural effects of six-week administration of oxytocin on core symptoms of autism. *Brain : A Journal of Neurology*, *138*(Pt 11), 3400–3412.
- 616 https://doi.org/10.1093/BRAIN/AWV249
- Wechsler, D. (2018). WISC-V-NL. Wechsler Intelligence Scale for Children, Fifth Edition,
 Dutch version. Amsterdam: Pearson Benelux B.V.
- Yamasue, H., Kojima, M., Kuwabara, H., Kuroda, M., Matsumoto, K., Kanai, C., Inada, N.,
 Owada, K., Ochi, K., Ono, N., Benner, S., Wakuda, T., Kameno, Y., Inoue, J., Harada,
 T., Tsuchiya, K., Umemura, K., Yamauchi, A., Ogawa, N., ... Yamasue, H. (2022).
 Effect of a novel nasal oxytocin spray with enhanced bioavailability on autism: a
 randomized trial. *Brain.* https://doi.org/10.1093/BRAIN/AWAB291
- Yamasue, H., Okada, T., Munesue, T., Kuroda, M., Fujioka, T., Uno, Y., Matsumoto, K.,
 Kuwabara, H., Mori, D., Okamoto, Y., Yoshimura, Y., Kawakubo, Y., Arioka, Y., Kojima,
 M., Yuhi, T., Owada, K., Yassin, W., Kushima, I., Benner, S., ... Kosaka, H. (2020).
 Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a
 randomized clinical trial. *Molecular Psychiatry*, *25*(8), 1849–1858.
 https://doi.org/10.1038/S41380-018-0097-2
- Yatawara, C. J., Einfeld, S. L., Hickie, I. B., Davenport, T. A., & Guastella, A. J. (2016). The
 effect of oxytocin nasal spray on social interaction deficits observed in young children
 with autism: a randomized clinical crossover trial. *Molecular Psychiatry*, 21(9), 1225–
 1231. https://doi.org/10.1028/MP.2015.162
- 633 1231. https://doi.org/10.1038/MP.2015.162

Table 1.

Demographic characteristics of the trial participants at baseline.

Mean baseline scores listed separately for the oxytocin and placebo treatment groups. *T*- and *p*-values correspond to independent sample *t*-tests assessing between-group differences in baseline scores.

			Placebo					
	N	mean ± SD	N	mean	±	SD	<i>t-</i> value	<i>p</i> -value
Age	38	10.48 ± 1.32	39	10.39	±	1.23	0.28	0.779
Gender	30 M / 8 F		31 M / 8 F					
Handedness	35 R / 3 L		33 R / 6 L					
WISC-V*								
Verbal IQ	37	105.84 ± 14.41	38	109.42	±	15.77	-1.03	0.308
Performance IQ	38	104.05 ± 15.36	38	101.66	±	12.75	0.74	0.462
ADOS-2								
Total	33	9.48 ± 3.78	32	9.16	±	4.15	0.33	0.740
Social Affect	31	7.13 ± 3.55	32	7.47	±	3.72	-0.37	0.712
Restricted and Repetitive Behavior	31	2.10 ± 1.19	31	1.71	±	1.30	1.22	0.226
Primary Outcome								
SRS-2	38	89.26 ± 21.66	39	87.87	±	20.03	0.29	0.771
Secondary outcomes - parent report								
RBS-R	38	27.29 ± 15.24	39	26.64	±	16.43	0.18	0.858
SCARED Parent	38	39.74 ± 21.74	39	45.15	±	18.31	-1.18	0.240
Secondary outcomes - self report								
SCARED child	38	38.29 ± 20.99	39	39.05	±	20.21	-0.16	0.872
ASCQ Anxious	38	13.45 ± 5.19	39	12.85	±	4.15	0.56	0.575
ASCQ Avoidant	38	13.79 ± 4.00	39	14.08	±	3.86	-0.32	0.749

ASCQ Secure	38	19.97 ± 3.50	39	19.23 ± 2.78	1.03	0.305
Attachment Mother Anxiety	38	4.74 ± 2.89	39	4.82 ± 2.78	-0.13	0.897
Attachment Mother Avoidance	38	9.05 ± 4.76	39	7.97 ± 4.03	1.07	0.286
Attachment Mother Secure	38	16.76 ± 4.24	39	17.87 ± 3.13	-1.31	0.195
					Pearson chi square	<i>p</i> -value
Comorbidity**	15		15		Pearson chi square 0.01	p-value 0.927
Comorbidity** Psychoactive Medication**	15 22		15 23		Pearson chi square 0.01 0.01	<i>p</i> -value 0.927 0.923

Data are shown as mean ± standard deviation. M male, F female, R right, L left, ADOS autism diagnostic observation schedule, SRS Social Responsiveness Scale, RBS-R Repetitive Behavior Scale-Revised, SCARED Screen for Child Anxiety Related Disorders, ASCQ Attachment Style Classification Questionnaire.

*WISC-V Wechsler Intelligence Scale for Children. The verbal intelligence quotient (IQ) was derived from the subtests Block design and Figure puzzles. The performance IQ was derived from the subtests Similarities and Vocabulary. **Detailed information on comorbidities and medication use is provided in **Supplementary Table 2.** ***Concomitant participation in psychosocial therapies were screened for and if present (minimum of one session/month), frequency was determined as number of sessions/month. Reported psychosocial therapies include: Theory of mind training; emotion recognition training; social skills training; cognitive behavioral therapy; psychotherapy; self-esteem training; mood regulation; music therapy; hippotherapy; autism coach.

Table 2.

Effects of oxytocin treatment on primary and secondary outcome measures of the double-blind phase I.

Mean change from baseline scores are listed separately for the oxytocin and placebo treatment groups, and separately for the post assessment session (immediately after the four-week treatment) and the follow-up assessment (four weeks after cessation of the treatment).

	Within-group									Between-group			
	Oxytocin				Placebo								
Outcome Measure	N	Mean	± SD	<i>t</i> -value	<i>p</i> -value	N	Mean :	± SD	t-value	<i>p</i> -value	Cohen's <i>d</i>	t-value	<i>p-</i> value
Post assessment													
Primary Outcome													
SRS-2	38	-4.08	± 10.0	5 -2.50	0.017	38	-4.55	± 10.23	-2.74	0.009	0.05	0.20	0.839
Secondary Outcomes - parent report													
RBS-R	38	-6.53	± 11.2	6 -3.57	0.001	38	-6.76 :	± 9.92	-4.20	0.000	0.02	0.10	0.923
SCARED Parent	38	-0.47	± 11.6	1 -0.25	0.803	38	-4.95 :	± 11.93	-2.56	0.015	0.38	1.66	0.102
Secondary Outcomes - self report													
SCARED Child	38	-4.74	± 11.4	7 -2.55	0.015	39	-3.38 :	± 11.32	-1.87	0.070	-0.12	-0.52	0.604
ASCQ Secure	38	-0.89	± 2.42	-2.27	0.029	39	-0.92 :	± 2.93	-1.97	0.057	0.01	0.05	0.963
ASCQ Anxious	38	-0.92	± 3.24	-1.75	0.088	39	-1.00 :	± 2.50	-2.50	0.017	0.03	0.12	0.905
ASCQ Avoidant	38	-0.29	± 3.73	-0.48	0.636	39	-1.08 :	± 3.30	-2.04	0.049	0.22	0.98	0.330
Attachment Mother Anxiety	38	0.76	± 2.95	1.59	0.120	39	-0.33 :	± 2.57	-0.81	0.423	0.40	1.74	0.086
Attachment Mother Avoidance	38	-0.21	± 3.18	-0.41	0.686	39	-0.82 :	± 3.94	-1.30	0.201	0.17	0.75	0.458
Attachment Mother Secure	38	0.24	± 4.18	0.35	0.729	39	-0.18 :	± 2.55	-0.44	0.663	0.12	0.53	0.598
Follow-up assessment													
Primary Outcome													
SRS-2	38	-6.76	± 11.19	9 -3.73	0.001	39	-5.38 :	± 13.42	-2.51	0.017	-0.11	-0.49	0.626
Secondary Outcomes - parent report													
RBS-R	38	-4.55	± 10.7	6 -2.61	0.013	39	-4.41 :	± 8.28	-3.33	0.002	-0.01	-0.07	0.948
SCARED Parent	38	-2.92	± 11.5	3 -1.56	0.127	39	-5.38 :	± 9.52	-3.53	0.001	0.23	1.02	0.309
Secondary Outcomes - self report													
SCARED Child	38	-5.97	± 9.84	-3.74	0.001	39	-6.36 :	± 13.38	-2.97	0.005	0.03	0.14	0.886
ASCQ Anxious	38	-1.00	± 3.92	-1.57	0.125	39	-2.38 :	± 3.75	-3.98	0.000	0.36	1.58	0.117

ASCQ Avoidant	38	-0.84 ± 4.04	-1.28	0.207	39	-1.46 ± 3.09	-2.95	0.005	0.17	0.76	0.452
ASCQ Secure	38	-1.37 ± 3.34	-2.53	0.016	39	-0.82 ± 3.78	-1.35	0.184	-0.15	-0.67	0.503
Attachment Mother Anxiety	38	0.84 ± 3.11	1.67	0.103	39	0.08 ± 3.07	0.16	0.877	0.25	1.09	0.281
Attachment Mother Avoidance	38	-0.61 ± 3.89	-0.96	0.343	39	-0.67 ± 3.50	-1.19	0.241	0.02	0.07	0.942
Attachment Mother Secure	38	0.66 ± 3.93	1.03	0.308	39	0.13 ± 2.83	0.28	0.779	0.16	0.68	0.498

Within-group *t*- and *p*-values correspond to single-sample *t*-tests assessing within-group change from baseline separately for the oxytocin and placebo group. Between-group *t*- and *p*-values correspond to independent sample *t*-tests assessing between-group differences in change from baseline scores. Cohen's *d* effect sizes (change from baseline_{OT}-change from baseline_{PL})/pooled SD) are reported where 0.2 is indicative of a small effect, 0.5 a medium effect and 0.8 a large effect. Data printed in bold show *p*-values or less than 0.05.

SRS Social Responsiveness Scale, RBS-R Repetitive Behavior Scale-Revised, SCARED Screen for Child Anxiety Related Disorders, ASCQ Attachment Style Classification Questionnaire. For all outcomes, except ASCQ secure and Attachment mother secure, negative change from baseline scores indicate pre-to-post improvement.

Figure 1

CONSORT flow diagram of participants in the trial.

Participants first underwent a double-blind phase (phase I) during which they were allocated to receive either oxytocin or placebo (four weeks of twice daily intranasal administration), followed by a four-week single-blind extension phase (phase II) during which all participants received four weeks of intranasal oxytocin. In both phases, treatment effects were assessed immediately after the four-week treatment (post) and at a follow-up session four weeks after cessation of the daily administrations (follow-up). For each assessment session, completed assessments are indicated separately for parent informant- and child self-reports.



Figure 2

Change in treatment responses according to the presence of concomitant psychosocial treatment.

Visualization of changes from baseline in parent-reported social responsiveness (SRS) of the double-blind phase (phase I), separately for children receiving only the oxytocin (n = 23) or placebo (n = 25) treatment and children receiving oxytocin (n = 15) or placebo (n = 13) treatment in combination with concomitant psychosocial treatment (pooled across the immediate post and four-week follow-up session). Lower scores indicate improvement. Vertical bars denote ± standard errors.



Figure 3

Change in treatment responses according to parent reported beliefs about the allocated treatment.

Visualization of changes from baseline in parent-reported social responsiveness (SRS) of the double-blind phase (phase I) at the post (immediately after the four week treatment) and four-week follow-up session, separately for each treatment group (actual spray: oxytocin or placebo) and according to parent reported beliefs about the allocated treatment (oxytocin or placebo): oxytocin_{spray}/oxytocin_{belief}: n = 15; oxytocin_{spray}/placebo_{belief}: n = 16; placebo_{spray}/oxytocin_{belief}: n = 13; placebo_{spray}/placebo_{belief}: n = 21. Lower scores indicate improvement. Vertical bars denote ± standard errors.



Figure 4

Treatment responses of the single-blind extension phase (phase II).

Visualization of changes from baseline in caregiver-reported social responsiveness (SRS) of the double-blind phase (phase I) and the single-blind extension phase (phase II), separately for each original treatment group (oxytocin-first, placebo-first) and assessment session (immediate post and four-week follow-up). Lower scores indicate improvement. Vertical bars denote \pm standard errors.

